Exarchou, Klaire
Hu, Haiyi
Stephens, Nathan A.
Moore, Andrew R.
Kelly, Mark
Lamarca, Angela
Mansoor, Wasat
Hubner, Richard
McNamara, Mairéad G.
Smart, Howard
Howes, Nathan R.
Valle, Juan W.
Pritchard, D. Mark http://orcid.org/0000-0001-7971-3561
Funding for this research was provided by:
Royal College of Surgeons of England (Freemasons' Royal Arch Research Fellowship with support from Sir John Fisher Foundation)
Article History
Received: 5 June 2022
Accepted: 9 July 2022
First Online: 27 July 2022
Compliance with ethical standards
:
: K.E. has received consultancy funding from Ipsen. A.R.M. has received consultancy funding from Ipsen. A.L. declares travel and educational support from Ipsen, Pfizer, Bayer, A.A.A., SirtEx, Novartis, Mylan and Delcath, speaker honoraria from Merck, Pfizer, Ipsen, Incyte, A.A.A., Q.E.D., Servier, Astra Zeneca and EISAI, advisory and consultancy honoraria from EISAI, Nutricia Ipsen, Q.E.D., Roche, Servier, Boston Scientific, Albireo Pharma, AstraZeneca, Boehringer Ingelheim and GENFIT, she is a member of the Knowledge Network and NETConnect Initiatives funded by Ipsen. WM has received consultancy funding from Ipsen, Novartis, Pfizer, Merck and B.M.S. Speakers’ Bureau. He has received travel grants from Merck and Ipsen as well as research funding from Nordic, M.S.D. R.H. has received consultancy funding from Ipsen and served on advisory boards for Ipsen. He has received conference attendance support. M.M.N. received research grant support from Servier, Ipsen, and NuCana. She has received travel and accommodation support from Bayer and Ipsen and speaker honoraria from Pfizer, Ipsen, NuCana, Mylan and Advanced Accelerator Applications (UK & Ireland) Ltd. She has served on advisory boards for Celgene, Ipsen, Sirtex, Baxalta, Incyte and Astra Zeneca; all outside of the scope of this work. J.W.V. reports personal fees from Agios, AstraZeneca, Baxter, Genoscience Pharma, Hutchison Medipharma, Imaging Equipment Ltd (AAA), Incyte, Ipsen, Mundipharma E.D.O., Mylan, Q.E.D., Servier, Sirtex, Zymeworks; and grants, personal fees, and non-financial support from NuCana, outside the submitted work. D.M.P. has received consultancy funding from Ipsen, Advanced Accelerator Applications and Mayoly Spindler laboratories and research funding from Trio Medicines Ltd. None of the other authors have any conflicts of interest to declare.
: No ethical approval was required for this retrospective study, but the project was registered and approved by the respective hospital Audit departments.